Healthcare
AZN Stock Analysis
AstraZeneca PLC · current price $162.69 (-1.09% today)
Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
★★★
Average
AZN Stock AnalysisAstraZeneca PLC · current price $162.69 (-1.09% today)
Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.
Reading AZN’s price and volume history…
Checking the areas that decide this thesis…
AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.
Reading AZN’s filings…
| Quarter | EPS | Est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-31 | $1.29 | $1.27 | +1.4% | Beat |
| 2026-06-30 | $1.31 | $1.25 | +4.8% | Beat |
AstraZeneca PLC (AZN) currently has a TickerMover Quant Score of 53/100, rated ★★★ Average. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.
TickerMover does not give buy or sell recommendations. AZN scores 53/100 (★★★ Average) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.
AZN's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.
Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.
Open the dashboard for AZN →
